BD Biosciences, Zyomyx to apply antibody expertise to high density protein biochips
Under the terms of this agreement, BDB will make available its growing antibody library to facilitate the development of Zyomyx' high-density protein biochips. Zyomyx will engage BDB to develop, manufacture, and supply antibodies for Zyomyx' research applications.
"This collaboration with Zyomyx strengthens our position as a leading content provider in the field of proteomic research, and builds on our recent efforts to expand the antibody libraries available through BDB," explains Deborah J. Neff, president, BD Biosciences. "We believe that this partnership will leverage Zyomyx proprietary array technology with our antibody libraries to provide innovative tools to researchers all over the world."
"BD Biosciences is a leading provider of antibody technologies against cellular and intracellular markers in human, mouse, and other species," says Lawrence K. Cohen, Ph.D., chief executive officer, Zyomyx. "Our collaboration with BD Biosciences will greatly expand our antibody resources and enhance our capability to develop superior protein biochips."
BDB, a division of BD (Becton, Dickinson and Company), provides innovative tools, systems and solutions supporting the life sciences around the world, accelerating the pace of discovery and diagnosis. From genes to proteins to cells, BDB offers integrated, high-value applications in drug discovery and development, flow cytometry systems, immune function monitoring, and functional genomics. With fiscal year 2000 revenues of approximately $550 million, BD Biosciences is comprised of Clontech Laboratories, Discovery Labware, Immunocytometry Systems, Pharmingen and Transduction Laboratories, names that have been known and trusted in the life sciences for years.
BD is a medical technology company that manufactures and sells a broad range of supplies, devices and systems for use by healthcare professionals, medical research institutions, industry and the general public.
Source: Zyomyx, Inc.